Cargando…

Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy

Exon-skipping via synthetic antisense oligonucleotides represents one of the most promising potential therapies for Duchenne muscular dystrophy (DMD), yet this approach is highly sequence-specific and thus each oligonucleotide is of benefit to only a subset of patients. The discovery that dystrophin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hildyard, John CW, Wells, Dominic J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Muscular Dystrophy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972457/ https://www.ncbi.nlm.nih.gov/pubmed/27525173 http://dx.doi.org/10.1371/currents.md.99d88e72634387639707601b237467d7

Ejemplares similares

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Clinic-Based Infant Screening for Duchenne Muscular Dystrophy: A Feasibility Study
por: Cyrus, Alissa, et al.
Publicado: (2012)

A Pilot Survey Study of Adherence to Care Considerations for Duchenne Muscular Dystrophy
por: Conway, Kristin, et al.
Publicado: (2018)

Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences
por: Henricson, Erik, et al.
Publicado: (2012)

The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys
por: Pane, Marika, et al.
Publicado: (2014)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Prednisone and Deflazacort in Duchenne Muscular Dystrophy: Do They Play a Different Role in Child Behavior and Perceived Quality of Life?
por: Sienko, Susan, et al.
Publicado: (2016)

Health Care Transition Experiences of Males with Childhood-onset Duchenne and Becker Muscular Dystrophy: Findings from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) Health Care Transitions and Other Life Experiences Survey
por: Paramsothy, Pangaja, et al.
Publicado: (2018)

Collective Statement Regarding Patient Access to Approved Therapies from the Center Directors of Parent Project Muscular Dystrophy’s Certified Duchenne Care Centers
por: Ionita, Cristian, et al.
Publicado: (2018)

The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish
por: Winder, Steve J, et al.
Publicado: (2011)

New Recommendation on Biological Materials Could Hamper Muscular Dystrophy Research
por: McCormack, Pauline, et al.
Publicado: (2016)

DuchenneConnect Registry Report
por: Rangel, Vanessa, et al.
Publicado: (2012)

Restoration of dystrophin expression using the Sleeping Beauty transposon
por: Muses, Sofia, et al.
Publicado: (2012)

Repression of nuclear CELF activity can rescue CELF-regulated alternative splicing defects in skeletal muscle models of myotonic dystrophy
por: Berger, Dara S., et al.
Publicado: (2012)

Alterations in the expression of leukemia inhibitory factor following exercise: comparisons between wild-type and mdx muscles
por: Hunt, Liam C, et al.
Publicado: (2011)

Speckle tracking analysis of the left ventricular anterior wall shows significantly decreased relative radial strain patterns in dystrophin deficient mice after 9 months of age
por: Spurney, Christopher, et al.
Publicado: (2012)

Voluntary wheel running in dystrophin-deficient (mdx) mice: Relationships between exercise parameters and exacerbation of the dystrophic phenotype
por: Smythe, Gayle M, et al.
Publicado: (2012)

The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice.
por: Radley-Crabb, Hannah G, et al.
Publicado: (2011)

Intramuscular Transplantation of Muscle Precursor Cells over-expressing MMP-9 improves Transplantation Success
por: Pichavant, Christophe, et al.
Publicado: (2011)

Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages
por: Wang, Bo, et al.
Publicado: (2011)

Human satellite cells: identification on human muscle fibres
por: Boldrin, Luisa, et al.
Publicado: (2012)

Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy
por: Philippi, Susanne, et al.
Publicado: (2012)

Guidance in Social and Ethical Issues Related to Clinical, Diagnostic Care and Novel Therapies for Hereditary Neuromuscular Rare Diseases: “Translating“ the Translational
por: McCormack, Pauline, et al.
Publicado: (2013)

Validity, Reliability, and Sensitivity of a 3D Vision Sensor-based Upper Extremity Reachable Workspace Evaluation in Neuromuscular Diseases
por: Han, Jay J., et al.
Publicado: (2013)

The Effects of Glucocorticoid and Voluntary Exercise Treatment on the Development of Thoracolumbar Kyphosis in Dystrophin-Deficient Mice
por: Brereton, Daniel, et al.
Publicado: (2012)

Proof of Concept of the Ability of the Kinect to Quantify Upper Extremity Function in Dystrophinopathy
por: Lowes, Linda P, et al.
Publicado: (2013)

Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice
por: Spitali, Pietro, et al.
Publicado: (2013)

Increased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation
por: Terrill, Jessica R., et al.
Publicado: (2016)

Are Soy Products Effective in DMD?
por: Winder, Steve J, et al.
Publicado: (2018)

Studies of pseudohypertrophic muscular dystrophy
por: Bonsett, Charles A., 1921-
Publicado: (1969)

The skeletal muscle phenotype of the DE50-MD dog model of Duchenne muscular dystrophy
por: Hildyard, John C.W., et al.
Publicado: (2022)

Identification of qPCR reference genes suitable for normalizing gene expression in the mdx mouse model of Duchenne muscular dystrophy
por: Hildyard, John C. W., et al.
Publicado: (2019)

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E.C., et al.
Publicado: (2021)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
por: Goyenvalle, Aurélie, et al.
Publicado: (2011)

Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy
por: Crawford, Abbe H., et al.
Publicado: (2022)

Serum inflammatory cytokines as disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy
por: Riddell, Dominique O., et al.
Publicado: (2022)

Longitudinal assessment of blood-borne musculoskeletal disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy
por: Riddell, Dominique O., et al.
Publicado: (2022)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Tracking progress: an update on animal models for Duchenne muscular dystrophy
por: Wells, Dominic J.
Publicado: (2018)

An update on Becker muscular dystrophy
por: Straub, Volker, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r0p13118u4t7okqjvltfpd4oh1